Buscar
Mostrando ítems 1-10 de 42
Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru
(Oxford University Press, 2022)
Objectives: The objective of this study was to analyse the cost-effectiveness (C-E) of ceftazidime/avibactam (CAZ/AVI)-based therapy versus colistin (COL)-based therapy for pneumonia and bacteraemia caused by carbapenem-resistant ...
Perfil de susceptibilidad de enterobacterias aisladas de muestras clínicas frente a Ceftazidime/Avibactam
(Pontificia Universidad Javeriana, 2021)
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
(MDPI, 2020-02)
Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin ...
Defining substrate specificity in the ctx-m family: The role of asp240 in ceftazidime hydrolysis
(American Society for Microbiology, 2018-06)
The natural diversification of CTX-M -lactamases led to the emergence of Asp240Gly variants in the clinic that confer reduced susceptibility to ceftazidime (CAZ). In this study, we compared the impact of this substitution ...
Estado del perfil de susceptibilidad in vitro de Enterobacterales frente a Ceftazidime/Avibactam
(Pontificia Universidad Javeriana, 2020)
“Determinación de la eficacia de Ceftazidime/Avibactam por el método de microdilución en caldo en cepas de enterobacterias y de Pseudomonas aeruginosa recibidas en el INSPI, año 2017”
(PUCE-Quito, 2018)
Las enterobacterias y Pseudomonas aeruginosa son patógenos comúnmente relacionados con infecciones asociadas a la atención en salud, y de mayor relevancia clínica debido a la resistencia que presentan a los antibióticos. ...
Nicho terapéutico de ceftazidima-avibactam frente a la multidrogo-resistencia en bacterias gram-negativas en Colombia
(MedicinaUniversidad El BosqueFacultad de Medicina, 2020)
La resistencia antibiótica es un gran problema de salud pública a
nivel mundial, debido a que aumenta la morbimortalidad por un
gran número de patologías, es el responsable de 700.000
muertes por año, y que se estima ...
Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?
(American Society for Microbiology, 2017-04)
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant ...
Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
(2022)
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of ...
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance
(2022)
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through ...